Intellia Therapeutics, Inc.
12.21USD
-0.5300 (-4.16%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 52.1M | 36.3M | 57.9M | 67.7M | 51.9M | 126.3M |
| Q1 | 11.3M | 12.6M | 28.9M | 16.6M | 15.0M | — |
| Q2 | 14.0M | 13.6M | 7.0M | 14.2M | 7.7M | — |
| Q3 | 13.3M | 12.0M | 9.1M | 13.8M | 9.8M | — |
| Q4 | 13.6M* | -1.9M* | 12.9M* | 23.0M* | 17.1M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -6.16 | -5.42 | -5.25 | -3.81 | -3.16 | -2.60 |
| Q1 | -1.96 | -1.17 | -1.12 | -1.10 | -.810 | — |
| Q2 | -1.33 | -1.40 | -1.52 | -.980 | -.800 | — |
| Q3 | -1.49 | -1.38 | -1.34 | -.920 | -.789 | — |
| Q4 | -1.47* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.49* |
| -1.30* |
| -.884* |
| -.761 |
| — |